Reference
- Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
- Colombat P, Brousse N, Morschhauser F, Franchi-Rezgui P. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years. Blood 2006; 108: 486a
- Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. NEJM 2005; 352: 441–449
- Kimby E, Jurlander J, Geisler C, Hagbberg H, Holte H, Lehtinen T, et al. Long term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon α-2: a randomized phase II study form the Nordic Lymphoma Group. Leuk Lymph, 49: 102–112
- Rohatiner A Z, Gregory W M, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
- Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, et al. Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958